In vitro inhibition of factor XIII retards clot formation, reduces clot firmness, and increases fibrinolytic effects in whole blood

Anesthesia and Analgesia

Volumn 109, Issue 4, 2009, Pages 1023-1028

  Jámbor, Csilla ^a   Reul, Viviane ^a   Schnider, Thomas W ^a,b   Degiacomi, Priska ^a   Metzner, Hubert ^c   Korte, Wolfgang C ^a,b  

^a CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c CSL BEHRING GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; BLOOD CLOTTING FACTOR 13; FIBRINOGEN RECEPTOR; NEUTRALIZING ANTIBODY; ANTIBODY; ANTITHROMBOCYTIC AGENT; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY; THROMBOPLASTIN;

ARTICLE; BLOOD; BLOOD CLOT LYSIS; BLOOD CLOTTING; BLOOD CLOTTING FACTOR 13 DEFICIENCY; BLOOD CLOTTING TIME; BLOOD SAMPLING; FIBRINOLYSIS; HUMAN; IN VITRO STUDY; INHIBITION KINETICS; PRIORITY JOURNAL; THROMBOCYTE; THROMBOELASTOGRAPHY; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; PREDICTION AND FORECASTING; ROC CURVE; SENSITIVITY AND SPECIFICITY; TIME;

ANTIBODIES; ANTIBODIES, MONOCLONAL; BLOOD COAGULATION; FACTOR XIII; FACTOR XIII DEFICIENCY; FIBRINOLYSIS; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PREDICTIVE VALUE OF TESTS; ROC CURVE; SENSITIVITY AND SPECIFICITY; THROMBELASTOGRAPHY; THROMBOPLASTIN; TIME FACTORS;

EID: 70349568133     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/ANE.0b013e3181b5a263     Document Type: Article

References (37)

1. Ganter MT, Hofer CK. Coagulation monitoring: current techniques and clinical use of viscoelastic point-of-care coagulation devices. Anesth Analg 2008;106:1366-1375
2. Nielsen VG, Cohen BM, Cohen E. Effects of coagulation factor deficiency on plasma coagulation kinetics determined via thrombelastography: critical roles of fibrinogen and factors II, VII, X and XII. Acta Anaesthesiol Scand 2005;49:222-231
3. Rugeri L, Levrat A, David JS, Delecroix E, Floccard B, Gros A, Allaouchiche B, Negrier C. Diagnosis of early coagulation abnormalities in trauma patients by rotation thrombelastography. J Thromb Haemost 2007;5:289-295
4. Bowbrick VA, Mikhailidis DP, Stansby G. Influence of platelet count and activity on thromboelastography parameters. Platelets 2003;14:219-224
5. Olorundare OE, Simmons SR, Albrecht RM. Cytochalasin D and E: effects on fibrinogen receptor movement and cytoskeletal reorganization in fully spread, surface-activated platelets: a correlative light and electron microscopic investigation. Blood 1992;79:99-109
6. Nielsen VG, Geary BT, Baird MS. Evaluation of the contribution of platelets to clot strength by thromboelastography in rabbits: the role of tissue factor and cytochalasin D. Anesth Analg 2000;91:35-39
7. Lang T, Toller W, Gutl M, Mahla E, Metzler H, Rehak P, Marz W, Halwachs-Baumann G. Different effects of abciximab and cytochalasin D on clot strength in thrombelastography. J Thromb Haemost 2004;2:147-153
8. Carroll RC, Craft RM, Chavez JJ, Snider CC, Kirby RK, Cohen E. Measurement of functional fibrinogen levels using the Thrombelastograph. J Clin Anesth 2008;20:186-190
9. Kettner SC, Panzer OP, Kozek SA, Seibt FA, Stoiser B, Kofler J, Locker GJ, Zimpfer M. Use of abciximab-modified thrombelastography in patients undergoing cardiac surgery. Anesth Analg 1999;89:580-584
10. Lang T, Johanning K, Mahla E, Nentwig B, Scheinichen D, Nurtsch A, von Depka M, Borscheuer A. Clot firmness cannot be estimated by fibrinogen concentration and platelet count. Haemostaseologie 2007;27:A60
11. Nielsen VG, Gurley WQ Jr, Burch TM. The impact of factor XIII on coagulation kinetics and clot strength determined by thrombelastography. Anesth Analg 2004;99:120-123
12. Francis CW, Marder VJ. Rapid formation of large molecular weight alpha-polymers in cross-linked fibrin induced by high factor XIII concentrations. Role of platelet factor XIII. J Clin Invest 1987;80:1459-1465
13. Schroeder V, Chatterjee T, Kohler HP. Influence of blood coagulation factor XIII and FXIII Val34Leu on plasma clot formation measured by thrombelastography. Thromb Res 2001;104:467-474
14. McDonagh J, McDonagh RP Jr, Delage JM, Wagner RH. Factor XIII in human plasma and platelets. J Clin Invest 1969;48:940-946
15. Nielsen VG, Kirklin JK, Hoogendoorn H, Ellis TC, Holman WL. Thrombelastographic method to quantify the contribution of factor XIII to coagulation kinetics. Blood Coagul Fibrinolysis 2007;18:145-150
16. Nomura S, Yanabu M, Miyake T, Miyazaki Y, Kawakatsu T, Kido H, Yamaguchi K, Fukuroi T, Kagawa H, Suzuki M, Kokawa T, Fukuhara S. Effect of cepharanthin and cytochalasin D on platelet internalization of anti-glycoprotein IIb/IIIa antibodies. Autoimmunity 1994;18:23-29
17. Fickenscher K, Aab A, Stuber W. A photometric assay for blood coagulation factor XIII. Thromb Haemost 1991;65:535-540
18. Harder S, Klinkhardt U, Graff J, Westrup D, Kirchmaier CM, Glusa E, Mascelli MA, Marciniak SJ, Just A, Losche W, Breddin HK. In vitro dose response to different GPIIb/IIIa-antagonists: inter-laboratory comparison of various platelet function tests. Thromb Res 2001;102:39-48
19. Moser M, Bertram U, Peter K, Bode C, Ruef J. Abciximab, eptifibatide, and tirofiban exhibit dose-dependent potencies to dissolve platelet aggregates. J Cardiovasc Pharmacol 2003;41: 586-592
20. Gerlach R, Raabe A, Zimmermann M, Siegemund A, Seifert V. Factor XIII deficiency and postoperative hemorrhage after neurosurgical procedures. Surg Neurol 2000;54:260-264
21. Rasche H, Haghou F, Gaus W, Dietrich M, Hoelzer D, Pflieger H, Kurrle E, Pindur G, Seifried E, Heimpel H. [Blood clotting factor XIII substitution in acute leukaemia: result of a randomized and controlled study]. Dtsch Med Wochenschr 1982; 107:1882-1886
22. Gerlach R, Tolle F, Raabe A, Zimmermann M, Siegemund A, Seifert V. Increased risk for postoperative hemorrhage after intracranial surgery in patients with decreased factor XIII activity: implications of a prospective study. Stroke 2002;33:1618-1623
23. Shen L, Lorand L. Contribution of fibrin stabilization to clot strength. Supplementation of factor XIII-deficient plasma with the purified zymogen. J Clin Invest 1983;71:1336-1341
24. Chakroun T, Gerotziafas GT, Seghatchian J, Samama MM, Hatmi M, Elalamy I. The influence of fibrin polymerization and platelet-mediated contractile forces on citrated whole blood thromboelastography profile. Thromb Haemost 2006;95:822-828
25. Ajzner E, Schlammadinger A, Kerenyi A, Bereczky Z, Katona E, Haramura G, Boda Z, Muszbek L. Severe bleeding complications caused by an autoantibody against the B subunit of plasma factor XIII: a novel form of acquired factor XIII deficiency. Blood 2009;113:723-725
26. Weisberg LJ, Shiu DT, Conkling PR, Shuman MA. Identification of normal human peripheral blood monocytes and liver as sites of synthesis of coagulation factor XIII a-chain. Blood 1987;70:579-582
27. Adany R. Intracellular factor XIII: cellular distribution of factor XIII subunit a in humans. Semin Thromb Hemost 1996;22:399-408
28. Muszbek L, Polgar J, Boda Z. Platelet factor XIII becomes active without the release of activation peptide during platelet activation. Thromb Haemost 1993;69:282-285
29. Hosoi S, Shinomiya K, Mikawa H. The use of monoclonal antibodies in demonstrating the effect of antibody heterogeneity on immune complex size. Clin Immunol Immunopathol 1984; 32:378-386
30. Adany R, Bardos H. Factor XIII subunit A as an intracellular transglutaminase. Cell Mol Life Sci 2003;60:1049-1060
31. Haas T, Fries D, Velik-Salchner C, Oswald E, Innerhofer P. Fibrinogen in craniosynostosis surgery. Anesth Analg 2008; 106:725-731, table of contents
32. Gorlinger K. [Coagulation management during liver transplantation]. Hamostaseologie 2006;26:S64-6
33. Kozek-Langenecker S. Management of massive operative blood loss. Minerva Anestesiol 2007;73:401-415
34. Craft RM, Chavez JJ, Bresee SJ, Wortham DC, Cohen E, Carroll RC. A novel modification of the Thrombelastograph assay, isolating platelet function, correlates with optical platelet aggregation. J Lab Clin Med 2004;143:301-309
35. Korte WC, Szadkowski C, Gahler A, Gabi K, Kownacki E, Eder M, Degiacomi P, Zoller N, Devay J, Lange J, Schnider T. Factor XIII substitution in surgical cancer patients at high risk for intraoperative bleeding. Anesthesiology 2009;110:239-245
36. Mosesson MW, Siebenlist KR, Hernandez I, Lee KN, Christiansen VJ, McKee PA. Evidence that alpha2-antiplasmin becomes covalently ligated to plasma fibrinogen in the circulation: a new role for plasma factor XIII in fibrinolysis regulation. J Thromb Haemost 2008;6:1565-1570
37. Lukacova D, Matsueda GR, Haber E, Reed GL. Inhibition of factor XIII activation by an anti-peptide monoclonal antibody. Biochemistry 1991;30:10164-10170